Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 4843

1.

Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium Vivax.

de Cassan SC, Shakri AR, Llewellyn D, Elias SC, Cho JS, Goodman AL, Jin J, Douglas AD, Suwanarusk R, Nosten FH, Rénia L, Russell B, Chitnis CE, Draper SJ.

Front Immunol. 2015 Jul 8;6:348. doi: 10.3389/fimmu.2015.00348. eCollection 2015.

PMID:
26217340
2.

Host-pathogen interactions in malaria: cross-kingdom signaling and mitochondrial regulation.

Luckhart S, Pakpour N, Giulivi C.

Curr Opin Immunol. 2015 Jul 22;36:73-79. doi: 10.1016/j.coi.2015.07.002. [Epub ahead of print] Review.

PMID:
26210301
3.

Engineering humoral immunity as prophylaxis or therapy.

Deal CE, Balazs AB.

Curr Opin Immunol. 2015 Jul 14;35:113-122. doi: 10.1016/j.coi.2015.06.014. [Epub ahead of print] Review.

PMID:
26183209
4.

Malaria vaccine clinical trials: what's on the horizon.

Moreno A, Joyner C.

Curr Opin Immunol. 2015 Jul 11;35:98-106. doi: 10.1016/j.coi.2015.06.008. [Epub ahead of print] Review.

PMID:
26172291
5.

Implementation workshop of WHO guidelines on evaluation of malaria vaccines: Current regulatory concepts and issues related to vaccine quality, Pretoria, South Africa 07 Nov 2014.

Ho MM, Baca-Estrada M, Conrad C, Karikari-Boateng E, Kang HN.

Vaccine. 2015 Jul 10. pii: S0264-410X(15)00924-X. doi: 10.1016/j.vaccine.2015.06.107. [Epub ahead of print]

6.

CD14(hi)CD16+ monocytes phagocytose antibody-opsonised Plasmodium falciparum infected erythrocytes more efficiently than other monocyte subsets, and require CD16 and complement to do so.

Zhou J, Feng G, Beeson J, Hogarth PM, Rogerson SJ, Yan Y, Jaworowski A.

BMC Med. 2015 Jul 7;13:154. doi: 10.1186/s12916-015-0391-7.

7.

Ad35.CS.01 - RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults.

Ockenhouse CF, Regules J, Tosh D, Cowden J, Kathcart A, Cummings J, Paolino K, Moon J, Komisar J, Kamau E, Oliver T, Chhoeu A, Murphy J, Lyke K, Laurens M, Birkett A, Lee C, Weltzin R, Wille-Reece U, Sedegah M, Hendriks J, Versteege I, Pau MG, Sadoff J, Vanloubbeeck Y, Lievens M, Heerwegh D, Moris P, Guerra Mendoza Y, Jongert E, Cohen J, Voss G, Ballou WR, Vekemans J.

PLoS One. 2015 Jul 6;10(7):e0131571. doi: 10.1371/journal.pone.0131571. eCollection 2015.

8.

Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates.

Longley RJ, Salman AM, Cottingham MG, Ewer K, Janse CJ, Khan SM, Spencer AJ, Hill AV.

Sci Rep. 2015 Jul 3;5:11820. doi: 10.1038/srep11820.

9.

Malaria Vaccines: Progressing on a Bumpy Road.

Corradin G, Nebie I.

EBioMedicine. 2014 Oct 23;1(1):6-7. doi: 10.1016/j.ebiom.2014.10.010. eCollection 2014 Nov. No abstract available.

10.

Acquisition of Functional Antibodies That Block the Binding of Erythrocyte-Binding Antigen 175 and Protection Against Plasmodium falciparum Malaria in Children.

Irani V, Ramsland PA, Guy AJ, Siba PM, Mueller I, Richards JS, Beeson JG.

Clin Infect Dis. 2015 Jul 1. pii: civ525. [Epub ahead of print]

PMID:
26136391
11.

Evaluation of the impact of codon optimization and N-linked glycosylation on functional immunogenicity of Pfs25 DNA vaccines in pre-clinical studies in mice by in vivo electroporation.

Datta D, Bansal GP, Kumar R, Ellefsen B, Hannaman D, Kumar N.

Clin Vaccine Immunol. 2015 Jul 1. pii: CVI.00185-15. [Epub ahead of print]

PMID:
26135972
12.

Vector-Mediated In Vivo Antibody Expression.

Schnepp BC, Johnson PR.

Microbiol Spectr. 2014 Aug;2(4). doi: 10.1128/microbiolspec.AID-0016-2014.

PMID:
26104192
13.

[The tropical traveling child: risks and prevention].

Alcoba G, Chappuis F.

Rev Med Suisse. 2015 May 6;11(473):1023-7. French.

PMID:
26103766
14.

Systems integration of innate and adaptive immunity.

Zak DE, Aderem A.

Vaccine. 2015 Jun 21. pii: S0264-410X(15)00782-3. doi: 10.1016/j.vaccine.2015.05.098. [Epub ahead of print]

PMID:
26102534
15.

MPLA shows attenuated pro-inflammatory properties and diminished capacity to activate mast cells in comparison with LPS.

Schülke S, Flaczyk A, Vogel L, Gaudenzio N, Angers I, Löschner B, Wolfheimer S, Spreitzer I, Qureshi S, Tsai M, Galli S, Vieths S, Scheurer S.

Allergy. 2015 Jun 17. doi: 10.1111/all.12675. [Epub ahead of print]

PMID:
26081583
16.

The Anopheles-midgut APN1 structure reveals a new malaria transmission-blocking vaccine epitope.

Atkinson SC, Armistead JS, Mathias DK, Sandeu MM, Tao D, Borhani-Dizaji N, Tarimo BB, Morlais I, Dinglasan RR, Borg NA.

Nat Struct Mol Biol. 2015 Jul;22(7):532-9. doi: 10.1038/nsmb.3048. Epub 2015 Jun 15.

PMID:
26075520
17.

Comparative Assessment of Transmission-Blocking Vaccine Candidates against Plasmodium falciparum.

Kapulu MC, Da DF, Miura K, Li Y, Blagborough AM, Churcher TS, Nikolaeva D, Williams AR, Goodman AL, Sangare I, Turner AV, Cottingham MG, Nicosia A, Straschil U, Tsuboi T, Gilbert SC, Long CA, Sinden RE, Draper SJ, Hill AV, Cohuet A, Biswas S.

Sci Rep. 2015 Jun 11;5:11193. doi: 10.1038/srep11193.

18.

Factors Associated With Provider Reporting of Child and Adolescent Vaccination History to Immunization Information Systems: Results From the National Immunization Survey, 2006-2012.

Cardemil CV, Cullen KA, Harris L, Greby SM, Santibanez TA.

J Public Health Manag Pract. 2015 Jun 9. [Epub ahead of print]

PMID:
26062097
19.

[Travelers with underlying medical conditions].

Cailhol J.

Rev Prat. 2015 Apr;65(4):523-8. French.

PMID:
26058202
20.

The structure of hookworm platelet inhibitor (HPI), a CAP superfamily member from Ancylostoma caninum.

Ma D, Francischetti IM, Ribeiro JM, Andersen JF.

Acta Crystallogr F Struct Biol Commun. 2015 Jun 1;71(Pt 6):643-9. doi: 10.1107/S2053230X1500271X. Epub 2015 May 20.

PMID:
26057788
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk